Roivant Sciences Ltd.
—Price / book
Market cap
—
Tangible equity
—
Price / tangible book
—
Price / book
—
Return on equity
-6.6%
Return on assets
-5.3%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ROIV stock price vs CME: inconclusive — current versus $4.09 implied using P/B multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CME's multiple
Implied fair value · at ROIV's multiple
Needs ROIV P/B.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · CME FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
—
Price / tangible book
—
Price / book
—
Return on equity
-6.6%
Return on assets
-5.3%
Efficiency ratio
—
Price / tangible book
Market cap
$18.75B
Tangible equity
$15.60B
Price / tangible book
1.20x
Price / book
0.65x
Return on equity
14.2%
Return on assets
2.1%
Efficiency ratio
—
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
CME GROUP INC. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.09x
5.68x
Net debt / EBITDA
Leverage against operating earnings
24.52x
27.88x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$4.54B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
S&P Global Inc.
ROIV vs SPGI
Moody's Corporation
ROIV vs MCO
MSCI Inc.
ROIV vs MSCI
Nasdaq, Inc.
ROIV vs NDAQ
$412.94M
$163.15B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.